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ABSTRACT: Zeolitic imidazolate framework-L (ZIF-L) could effectively improve the stability, 12 
controlled release and anticancer activity of natural hydrophobicity drugs in drug delivery systems 13 
(DDS). A simple and universal strategy was developed to prepare the curcumin-loaded ZIF-L 14 
(CCM@ZIF-L) by antisolvent coprecipitation method, which was different from the traditional 15 
approaches. The microcrystal molecules of curcumin were used as the core of ZIF-L growth to 16 
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form CCM@ZIF-L, which has a very high drug encapsulation efficiency of 98.21% and a regular 17 
leaf or cruciate flower-like structure. The formation of CCM@ZIF-L with distinct composite 18 
structure was supported by SEM, TEM, FTIR, PXRD and zeta-potential. Due to the protective 19 
effect of ZIF-L, CCM@ZIF-L exhibited excellent stability and about a 5-fold increase in 20 
temperature stability over free curcumin. CCM@ZIF-L exhibited controlled drug release behavior 21 
in simulated in vitro tumor microenvironments (almost 81.2 % drug release over a period of 72 h). 22 
Furthermore, confocal laser-scanning microscopy (CLSM) results and cytotoxicity experiments 23 
confirmed that the encapsulated curcumin showed a significant improvement in cellular uptake 24 
and anticancer activity against A549 cancer cells. Moreover, the curcumin encapsulated in ZIF-L 25 
exhibited remarkable cellular antioxidant activity based on MGC-803 cell models. This work 26 
presents a novel approach to solve the drug loading problem employing ZIF-L, and exhibits 27 










1. Introduction 37 
With the continuing deterioration of the global environment and changes in people’s lifestyle, 38 
a wide range of cancers have become a persistent predicament with regards to human health.1-2 A 39 
growing number of natural bioactive molecules are considered promising candidates for cancer 40 
treatment, because they showed less toxicity to non-cancerous cells compared to more 41 
conventional synthetic compounds.3-4 However, direct administration of some natural hydrophobic 42 
drugs suffer from some intrinsic limitations, including poor solubility, compromised physiological 43 
stability and low bioavailability. In response, a variety of drug delivery systems (DDS) such as 44 
polymer nanoparticles, liposomes, and metal organic frameworks (MOFs) have been realized to 45 
address some of these limitations by improving dispersibility in aqueous media, stabilizing the 46 
drug through encapsulation and facilitating enhanced cellular uptake.5-16 47 
MOFs are constructed using organic ligands and metal ions and exhibit unique features such 48 
as uniform shapes and pore sizes, improved bioavailability and controlled drug release.17-22,23 49 
There are two tactics that have been commonly pursued to achieve effective drug delivery 50 
employing MOFs.24-25 In the first method, the drug is absorbed by pre-synthesized MOFs. This 51 
tactic is appropriate for drugs that are relatively small in size.26 However, this approach can cause 52 
significant drug leakage during the final washing step, because the pores of the pre-synthesised 53 
MOFs are too large relative to the drug to be carried. This can result in a low encapsulation 54 
efficiency and ‘burst-release’ behavior.25 An alternative tactic is to have the drug in question 55 
encapsulated in-situ during the assembly of MOFs.27-33 Employing this tactic could accomplish 56 
the loading of drugs of various sizes into MOFs regardless of pore size, avoiding excessive drug 57 
leakage through ‘burst-release’ prior to the degradation of MOFs. Nonetheless a strong interaction 58 
between MOFs and drugs is essential in order to achieve successful in-situ encapsulation, which 59 
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is typically limited to drugs with specific functional groups (-COOH, -SO3H, C=O, etc.) or 60 
opposite charge. It is worth noting that a majority of the drug loading processes employing MOFs 61 
are carried out in organic solvents.27-31  62 
Zeolitic Imidazolate Framework L (ZIF-L), is formed by Zn2+ and 2-methylimidazole (2-63 
MIM) in an aqueous solution at a relatively low ratio of 2-MIM/Zn2+.34 ZIF-L has a pore structure 64 
similar to ZIF-8, with long-term physical stability, resistance to thermal degradation, and high 65 
loading efficiency and has been extensively researched for applications such as: gas separation and 66 
water treatment.34-35 However, few researches have demonstrated that ZIF-L could be a potential 67 
candidate for drug delivery systems.  68 
We developed a simple and straightforward methodology for the encapsulation of 69 
hydrophobic drugs in ZIF-L using an antisolvent co-precipitation method under mild conditions. 70 
Curcumin (CCM) was chosen as a model drug in this study because of its hydrophobicity, low 71 
bioavailability and rapid degradation under physiological pH conditions.40 As a natural bioactive 72 
compound, curcumin has extensive therapeutic uses, such as antitumor, antioxidation and 73 
antibacterial applications.36-39 We used crystal seeded growth of ZIF-L MOFs in aqueous media 74 
to achieve the drug (i.e. curcumin) loading process. The microcrystal particles of curcumin were 75 
chosen as the core of ZIF-L growth. The ZIF-L in-situ self-assembly based on microcrystal 76 
particles of curcumin was achieved by a co-precipitation method to obtain the curcumin-loaded 77 
ZIF-L (CCM@ZIF-L). As shown in Scheme 1, this drug delivery system was assembled by in-78 
situ encapsulation, which synchronized the process of ZIF-L synthesis and drug loading. This new 79 
designed CCM@ZIF-L DDS had the following advantages: (1) The use of microcrystal particles 80 
overcome the limitations of traditional drug loading with MOFs, achieving an ultrahigh drug 81 
encapsulation efficiency of 98.2 %. (2) This novel encapsulation approach enhanced the 82 
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physiological stability, cellular uptake and targeted anticancer activity of the drug. (3) Controlled 83 
drug release was observed in tumor cells, due to pH-responsive degradation of ZIF-L. 84 
Consequently, this study offers an effective approach to broaden the applications of ZIFs for 85 
anticancer therapy and exhibited great potential of ZIF-L as a drug carrier platform. 86 
 87 
Scheme 1. Schematic outline for the synthesis and assembly of CCM@ZIF-L and its pH-88 
responsive drug release mechanism. 89 
2. Experimental section 90 
2.1 Materials and Cell Culture 91 
Curcumin (reagent grade 98 %), 2-Methylimidazole (2-MIM, reagent grade 98 %), zinc 92 
nitrate hexahydrate (Zn(NO3)2·6H2O, analytical grade), 2,2-Diphenyl-1-picrylhydrazyl radical 93 
(DPPH, reagent grade 96 %), tyrosinase (25 KU, from mushroom) and 3, 4-dihydroxy-l-94 
phenylalanine (L-DOPA, reagent grade 99 %) were obtained from Aladdin Inc. (Shanghai, China). 95 
2,2-azobis (2-amidinopropane) dihydrochloride (ABAP) and 2,7-dichlorodi-hydrofluorescein 96 
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diacetate (DCFH-DA) were obtained from Sigma-Aldrich (St. Louis, MO, USA). Propidium 97 
Iodide (PI) and the Cell Counting Kit-8 (CCK-8) were obtained from Dojindo Laboratories 98 
(Kumamoto, Japan). RPMI-1640 culture media, trypsin-EDTA (0.05% (w/v)), fetal bovine serum 99 
(FBS), penicillin and streptomycin were purchased from Gibco (NY, USA). A549 cells (human 100 
alveolar basal epithelial cells) and MGC-803 (human gastric cancer cell) were obtained from the 101 
Cell Resource Center, Peking Union Medical College, and cultured in RPMI-1640 media 102 
supplemented with 10 % FBS and 1% (w/v) penicillin and streptomycin in a 5 % CO2 atmosphere, 103 
at 37 ℃. All other chemicals were of analytical grade and purchased from Beijing Chemical 104 
Works (Beijing, China), and were applied without further purification.  105 
2.2 HPLC analysis 106 
A curcumin stock solution was prepared by dissolving 5 mg of curcumin in methanol in a 100 107 
mL brown volumetric flask, which was then further diluted into various standard solutions at 1, 2, 108 
3, 4, 5 μg/mL with methanol. Curcumin was analyzed by HPLC (LC-20A, Japan), using a Venusil 109 
XBP C18 column (4.6 × 250 mm, 5 μm) with a mobile phase made of 0.5 % acetic acid (A) and 110 
acetonitrile (B) with an isocratic elution program at 44:56 for solutions A and B respectively. The 111 
flow rate was 1.0 mL/min, and the column temperature maintained isothermally at 35 °C. 112 
Curcumin was detected using a UV-vis detector at 428 nm. As shown in Figure S1, a good 113 
linearity was observed over the range of 1-5 μg/mL (R 2 = 0.9999). 114 
 115 
2.3 Synthesis of Curcumin loaded Zeolitic Imidazolate Framework-L (CCM@ZIF-L) 116 
Due to its highly hydrophobic nature, we produced a curcumin stock solution by dissolving 117 
20 mg of curcumin in 10 mL of methanol. Solutions of Zn(NO3)2·6H2O (30 mg/mL) and 2-MIM 118 
(66 mg/mL) were prepared using deionized water. In order to create microcrystal molecules of 119 
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curcumin in an aqueous solution, 10 mL of the curcumin stock solution was added into 50 mL of 120 
the Zn(NO3)2 solution under vigorous stirring for 5 min. The vigorously stirred mixture was then 121 
drop-wise added into the 2-MIM aqueous solution (50 mL) under continuous stirring for 30 122 
minutes. The reaction mixture was centrifuged, and the brick-red precipitate (CCM@ZIF-L) was 123 
washed thoroughly thrice with deionized water. The supernatant was collected to determine the 124 
drug loading efficiency (DLE). The DLE of CCM@ZIF-L was calculated according to the 125 
following equation (1). 126 
 127 
Do I get it right that what you really calculated was:  128 
DLE % =
total	amount of curcumin	added	‐	curcumin	in	supernatant





total amount of curcumin	added
×100%	131 
The synthesized CCM@ZIF-L was dispersed in deionized water and immediately analysed by 132 
scanning electron microscopy (SEM), transmission electron microscopy (TEM), confocal laser 133 
scanning microscopy (CLSM), and dynamic light scattering (DLS). The CCM@ZIF-L precipitate 134 
required for other analyses was freeze-dried prior to use. Furthermore, a pure ZIF-L was 135 
synthesized in the same manner as described above for comparison. All operations were conducted 136 
at room temperature. 137 
 138 
2.4 Characterization 139 
Fluorescence spectra and UV−vis absorption spectra were recorded using a RF-1501 140 
spectrofluorometer (Shimadzu, Kyoto, Japan) and a UV-2450 spectrophotometer (Shimadzu, 141 
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Kyoto, Japan), respectively. The morphology of CCM@ZIF-L was characterized employing a 142 
Hitachi HT7700 TEM (Hitachi, Tokyo, Japan), a Hitachi S-4700 SEM (Hitachi, Tokyo, Japan), 143 
and a Leica SP8 CLSM (Leica, Wetzlar, Germany). In order to determine the Zeta potentials of 144 
CCM@ZIF-L and ZIF-L, Dynamic Light Scattering (DLS) was carried out employing a Nano-ZS 145 
2000 (Malvern Instruments, Malvern, UK). FTIR (Fourier-transform infrared) spectra were 146 
performed on a Nicolet 6700 FTIR spectrometer (Waltham, MA, USA) equipped with a DLaTGS 147 
detector. The samples for FTIR analysis were prepared with KBr and compressed into tablets 148 
before analysis. An X-ray diffractometer (Bruker XRD, D8 ADVANCE) (Karlsruhe, Germany) 149 
equipped with a copper target X-ray tube set at 40 kV and 40 mA, employing Cu Kα radiation was 150 
used to obtain powder X-ray diffraction patterns (PXRD). All PXRD analysis were done in the 2θ 151 
angle range between 5˚ and 30˚ with a scan rate of 10˚ /min and a step size of 0.02˚.  152 
 153 
2.5 In vitro stability 154 
The stability of free curcumin and CCM@ZIF-L in phosphate buffer saline (PBS, 0.02 M) at 155 
different temperatures (25 °C, 45 °C, 65 °C or 85 °C), pH (5.4, 6.4, 7.4 or 8.4) and light conditions 156 
(dark, light or UV light at 254 nm) was analysed by monitoring the changes in absorbance at 428 157 
nm. The CCM@ZIF-L solutions were prepared by dispersing the previously freeze-dried samples 158 
in deionized water while being stirred. The free curcumin solution was prepared by dispersing 1 159 
mL of the curcumin stock solution into 50 mL of deionized water (final concentration: 1 mg/L 160 
curcumin in 2% (v/v) methanol) under the same conditions as CCM@ZIF-L. The curcumin 161 
concentration encapsulated in CCM@ZIF-L was evaluated by HPLC after disintegrated of 162 
CCM@ZIF-L in 1 M hydrochloride.  163 
2.6 In vitro Drug Release 164 
 9
The in vitro pH-responsive release behavior of CCM@ZIF-L was investigated by a 165 
previously described method, but adjusted for curcumin.41  Briefly, 10 mg of CCM@ZIF-L were 166 
dispersed into 50 mL of PBS (0.02 M, pH=7.4 or 5.0), at 37 °C while being gently shaken. Due to 167 
the poor solubility of curcumin in water, the dispersive stability of the released curcumin was 168 
significantly improved by adding Tween-80 (1.0 wt%) into PBS. The relative percentage of the 169 
accumulative release of curcumin was calculated as a function of incubation time. All operations 170 
were performed in triplicate.  171 
 172 
2.7 Biocompatibility test 173 
The biocompatibility of ZIF-L on basal lung cancer cells (A549 cell line) was examined using 174 
a cell counting kit (CCK-8).42 A549 cells were seeded in 96-well plates at a density of 4000 cells 175 
per well and incubated in the RPMI-1640 culture medium for 12 h at 37 °C. The cells were exposed 176 
to ZIF-L (0-100 µg/mL) for 72 h at 37 °C, following which the spent medium was replaced by 177 
fresh RPMI-1640 medium. Then ten µL CCK-8 was added and incubated for another 1 h at 37 °C. 178 
A microplate reader was used to measure the absorbance of each well at 450 nm. The cell viability 179 
was calculated according to the following equation (2). 180 




Where the culture media treated with DMSO represented the control group. The mean and 182 
standard deviation from three-well replicates were calculated.  183 
 184 
2.8 In vitro cytotoxicity study  185 
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A cytotoxicity assay was conducted to investigate the in vitro anticancer ability of both free 186 
curcumin and CCM@ZIF-L on A549 cells.24, 43 A549 cells were seeded into 96-well plates with a 187 
cell loading of 4000 per well and then incubated in RPMI-1640 culture medium for 12 h at 37 °C. 188 
After that, fresh medium containing various concentrations of free curcumin or CCM@ZIF-L was 189 
used to replace the initial culture medium at an equivalent concentration of curcumin for all 190 
samples varying from 1 to 5 µg/mL and incubated for 72 h at 37 °C, after which the spent culture 191 
medium was replaced with fresh medium containing 10 µL of CCK-8. The microtiter plates were 192 
then incubated for another 1 h at 37 °C before the absorbance was read at 450 nm and cell viability 193 
was calculated using the equation above (2). 194 
 195 
2.9 Cellular uptake study 196 
Cellular uptake of curcumin from CCM@ZIF-L into A549 cells was determined employing 197 
CLSM according to a previously described method, adjusted for curcumin.44 A549 cells (5×104 198 
cells per well in Laser confocal dishes) were incubated in RPMI-1640 culture medium and allowed 199 
to adhere for 12 h after which the culture medium was replaced by fresh medium containing free 200 
curcumin or CCM@ZIF-L, containing a final curcumin concentration equivalent to 5 μg/mL. The 201 
cells were cultured for 4 h and then washed thrice with fresh PBS. After that, the cells were fixed 202 
with 4 % formaldehyde (800 µL per well) for 30 min at room temperature and washed again three 203 
times with PBS. Subsequently, the fluorescent dye PI (200 µL) was used to stain the cells for 15 204 
min in the absence of light. Prior to imaging, all wells were washed thrice with PBS. Images were 205 
captured by exciting PI at 488 nm and curcumin at 442 nm, and measuring the emitted light at 630 206 
nm and 475 nm for PI and curcumin respectively.  207 
 208 
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2.10 Cellular Antioxidant Activity 209 
We used a previously described approach to investigate the antioxidant activity of free 210 
curcumin and CCM@ZIF-L in the living cells.45-46 This method used an oxidized cell model 211 
employing ABAP, which generates intracellular hydrogen peroxide free radicals. DCFH-DA is 212 
readily internalized by cells and converted into non-fluorescent DCFH by intracellular esterases 213 
after which DCFH can then be oxidized to form fluorescent DCF. If cells were treated with 214 
antioxidants (curcumin) from the outset, the oxidation of DCFH into DCF could be prevented. The 215 
antioxidant activity of added antioxidants could be ascertained through a reduction in DCF 216 
fluorescence. 217 
For our study the human gastric cancer cell line MGC-803 was chosen to evaluate the cellular 218 
antioxidant capacity (CAA) as described elsewhere.47 Cells (4000 cells per well) were seeded into 219 
96-well microtitre plates and incubated in RPMI-1640 culture medium for 24 h. After that, the 220 
spent culture medium was discarded and replaced by 100 µL fresh medium containing curcumin, 221 
or CCM@ZIF-L, or ZIF-L (equivalent concentration of curcumin as 2 μg/mL and/or the same 222 
amount of ZIF-L) and incubated for a further 24 h. After 24 h the cells were washed thrice with 223 
PBS and replaced with fresh medium containing DCFH-DA (25 µM, 100 µL) and incubated for 1 224 
h. Then, the wells were washed three times with PBS, before being treated with ABAP (600 µM, 225 
100 µL) in fresh medium. The fluorescent intensity was measured at an excitation wavelength and 226 
an emission wavelength of 485 nm and 355 nm respectively, every 5 minutes for 1 h. Negative 227 
controls were treated with DCFH-DA and ABAP without the addition of curcumin, while blank 228 
controls were treated with DCFH-DA only. The resultant time-fluorescence intensity curve was 229 
integrated to obtain the area, and then the CAA units could be calculated according to the following 230 






∫As represents the integral area of the fluorescence value-time curve after adding different 233 
concentrations of antioxidant.  234 
∫Ac represents the integral area of the fluorescence value-time curve associated with the 235 
experimental ‘control’ 236 
∫Ab represents the integral area of the fluorescence value-time curve associated with the 237 
experimental ‘blank’. 238 
The mean and standard deviation from three-well replicates were calculated. 239 
 240 
2.11 Tyrosinase inhibitory activity 241 
The catalytic activity of tyrosinase is key to control the production of melanin, and curcumin 242 
is known to reduce the production of melanin by inhibiting the activity of tyrosinase.48-49 The 243 
tyrosinase inhibitory activity assays of curcumin and CCM@ZIF-L were carried out using L-244 
DOPA as substrate.48 Curcumin and CCM@ZIF-L were dissolved in ethanol and then diluted to 245 
obtain a range of curcumin-equivalent concentrations (10, 20, 30, 40, 50 μg/mL) with PBS (0.05 246 
mM, pH 6.8). For the tyrosinase inhibitory activity assay a solution of 1 mL L-DOPA (1.0 mM) in 247 
PBS (0.05 mM, pH 6.8) and 0.5 mL of test sample (curcumin or CCM@ZIF-L) was incubated for 248 
5 min at 37 °C while continuously agitated. Then, 0.5 mL of tyrosinase (100 Units/mL) in PBS 249 
(0.05 mM, pH 6.8) was added and kept at 37 °C for 10 min while continuously agitated, after 250 
which the absorbance was measured at 475 nm and the inhibition of tyrosinase activity was 251 






Ai represents the absorbance of the reaction mixture containing sample, while A0 represents 254 
the absorbance of a control with no added sample. 255 
 256 
2.12 Statistical analysis 257 
All data are presented as mean ± standard deviation. The level of statistical significance for 258 






3. Results and discussion 265 
3.1 Synthesis and characterization of CCM@ZIF-L 266 
 267 
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Figure 1. TEM images of microcrystals of curcumin (A) and the growing CCM@ZIF-L (B). (C) 268 
Photo of curcumin in methanol stock solution (orange) and CCM@ZIF-L in deionized water (brick 269 
red). TEM images of CCM@ZIF-L (D, G), SEM images of CCM@ZIF-L (E, H) and CLSM 270 
images of CCM@ZIF-L (F, I). 271 
The microcrystals of hydrophobic curcumin were successfully loaded into ZIF-L using an 272 
antisolvent coprecipitation method to produce CCM@ZIF-L. TEM and SEM were used to 273 
characterize the formation process and the morphology of CCM@ZIF-L. As the reaction time 274 
increased, the stick-like microcrystals of curcumin were gradually encapsulated by ZIF-L (Figure 275 
1 A, B). The successful encapsulation of curcumin into ZIF-L frameworks coincided with a color 276 
change from orange to brick red (Figure 1 C). The prepared CCM@ZIF-L has a regular smooth 277 
ovoid structure (Figure 1 D, E) of which a proportion developed a cruciate flower-like structure 278 
(Figure 1 G, H), which can be ascribed as two microcrystals of curcumin assembled 279 
simultaneously during the growth of CCM@ZIF-L. TEM and SEM also confirmed that the size of 280 
CCM@ZIF-L is about 4 μm. The formation of CCM@ZIF-L was also observed by CLSM based 281 
on the fluorescence characteristic of curcumin.50 CCM@ZIF-L maintained the same morphology 282 
and size as observed by SEM and TEM, confirming that the microcrystals of curcumin were evenly 283 
encapsulated by ZIF-L (Figure 1 F, I). The DLE of CCM@ZIF-L was determined to be 98.2%, 284 
which makes ZIF-L a very suitable carrier for very hydrophobic compounds in medical 285 
applications. The UV−vis spectra of CCM@ZIF-L, ZIF-L and curcumin are shown in Figure S2 286 
A. The distinguishing absorption peaks of both curcumin and ZIF-L appeared at 428 and 213 nm 287 
respectively. However, CCM@ZIF-L had the same characteristic absorption peaks as ZIF-L at 288 
213 nm, indicating that curcumin was encapsulated successfully into the ZIF-L framework. 289 
Curcumin, ZIF-L and CCM@ZIF-L were also characterized by means of fluorescence. The 290 
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characteristic fluorescence peaks of curcumin were centered at 420 nm and 550 nm, while ZIF-L 291 
had an obvious peak at 440 nm (Figure S2 B). CCM@ZIF-L had a wide peak at 565 nm, which 292 
generated a small but noticeable red shift possibly due to the interaction between curcumin and 293 
ZIF-L, further evidencing the incorporation of curcumin into ZIF-L. The successful encapsulation 294 
of curcumin into ZIF-L was confirmed by FTIR. The characteristic peaks of ZIF-L were observed 295 
at 3177, 2923 and 1566 cm−1 (Figure 2 A), which correspond to aromatic C-H stretching, aliphatic 296 
C-H stretching and C-N stretching of imidazole respectively.34 The characteristic curcumin spectra 297 
with bands at 3504, 1628, 1602 cm−1 corresponded to vibrations of free hydroxyl group of phenols, 298 
CO stretching and aromatic CC stretching respectively.51 Other peaks associated with curcumin 299 
were observed at 1282 and 1154 cm−1, attributing to aromatic C-O stretching and C-O-C stretching 300 
respectively.37 The FTIR spectrum of CCM@ZIF-L showed peaks at 3211, 2923, 1568 cm−1 301 
corresponding to aromatic C-H stretching, aliphatic C-H stretching and C-N stretching of 302 
imidazole respectively, which are similar to the characteristic peaks of ZIF-L. The disappearance 303 
of the characteristic peaks of curcumin in CCM@ZIF-L reiterated the effective encapsulation of 304 
curcumin by ZIF-L. The successful construction of CCM@ZIF-L was also verified by XRD, as 305 
shown in Figure 2 B. The characteristic peaks of ZIF-L at 2θ values of 10.54, 12.80, 18.00, which 306 
were obviously different from curcumin (7.98, 8.90, 15.94 and 17.12).52 There was no change in 307 
the XRD pattern of CCM@ZIF-L (10.38, 12.72 and 18.02) compared to ZIF-L, demonstrating that 308 
the overall framework stability had minimum impact on its crystallinity. The zeta-potential of 309 
CCM@ZIF-L was determined by DLS. The zeta potential value of CCM@ZIF-L (+4.1 mV) was 310 
similar to that of ZIF-L (+3.8 mV) (Figure 2 C), confirming that curcumin was not merely 311 




Figure 2. (A) FTIR spectra of curcumin, ZIF-L and CCM@ZIF-L. (B) XRD patterns of curcumin, 315 
ZIF-L and CCM@ZIF-L. (C) Zeta potential of ZIF-L and CCM@ZIF-L. 316 
3.2 Stability enhancement of curcumin by ZIF-L encapsulation 317 
Curcumin is very unstable in aqueous solution and easily hydrolyzed into smaller molecules 318 
such as ferulic acid and vanillin. Temperature, pH and light will accelerate the decomposition of 319 
curcumin in aqueous solution, however changes in the microenvironment (such as encapsulation) 320 
can improve the stability of curcumin.53 The stability of free curcumin and CCM@ZIF-L under 321 
different environmental conditions (temperature, pH or light) were determined by monitoring the 322 
change in curcumin over time. The relative intensity of CCM@ZIF-L is about 5 times than that of 323 
free curcumin after thermal treatment for 4 h (Figure 3A), signifying that the encapsulation of ZIF-324 
L improved the temperature stability of curcumin. When the pH value increased from 5.4 to 8.4. 325 
the relative intensity of free curcumin gradually decreased (Figure 3B), while the relative intensity 326 
of CCM@ZIF-L gradually decreased without significant change. Due to the protective effect of 327 
ZIF-L, CCM@ZIF-L exhibited higher pH stability than free curcumin in an aqueous environment. 328 
The relative intensity of CCM@ZIF-L is about 3 times that of free curcumin after 4 hours in Figure 329 
3C. Thus, ZIF-L could efficiently protect curcumin by avoiding photodegradation. Moreover, the 330 
stability enhancement of CCM@ZIF-L was further supported by the change of relative intensity 331 
with time under different conditions (temperature, pH or light) in Figure S3-5. 332 
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 333 
Figure 3. Stability of free curcumin and CCM@ZIF-L in PBS solution at different temperatures 334 
(A), pH (B) or light (C) after 4 h.  335 
3.3 pH-responsive release of curcumin from CCM@ZIF-L 336 
 337 
Figure 4. The in vitro pH-response release profiles of curcumin from CCM@ZIF-L at different 338 
pH (pH 5.0 or 7.4) in PBS containing 1 wt % of Tween-80. 339 
The pH-responsive release of curcumin from CCM@ZIF-L was investigated in an in vitro 340 
drug release experiment, which was carried out in PBS solution at different pH conditions (pH 5.0 341 
or 7.4).30 Meanwhile, the addition of Tween-80 (1 wt%, PBS) was used to improve the stability of 342 
free curcumin, providing an excellent monitoring condition for drug released from CCM@ZIF-L 343 
in an aqueous environment.37 pH 5.0 was chosen to simulate the acidic condition in tumor cells, 344 
while pH 7.4 represents the physiological pH. The cumulative drug release of CCM@ZIF-L 345 
reached to 81.2 % after 72 h at pH 5.0. In comparison only 20.8 % of curcumin was released after 346 


























72 h in PBS at pH 7.4 (Figure 4), indicating that CCM@ZIF-L CCM@ZIF-L achieved pH-347 
responsive release. Therefore, the controlled drug release behavior could be exploited to enhance 348 
cytotoxicity toward tumor cells.54-55 349 
3.4 In vitro cytotoxicity study 350 
The anticancer activity of curcumin and CCM@ZIF-L against A549 cells was investigated 351 
through in vitro cytotoxicity experiments. Prior to undertaking the in vitro cytotoxicity 352 
experiments, we evaluated the biocompatibility of ZIF-L in A549 cells At ZIF-L concentrations 353 
below 50 μg/mL all of cell survival rates exceed 80 % (Figure 5A), indicating that ZIF-L has good 354 
biocompatibility and is suitable as a safe drug carrier for cancer therapy. As the curcumin 355 
concentration (free and encapsulated) increased from 1 to 5 μg/mL, the viability of A549 cells 356 
decreased (Figure 5B) More specifically, CCM@ZIF-L showed the lower viability with regards 357 
to A549 cells than free curcumin at the same concentration. CCM@ZIF-L induced almost 48.2 % 358 
of cell death against A549 cells compared to only 4.9 % cell death caused by curcumin at the 359 
equivalent concentration of 2 μg/ml. The cytotoxicity was more pronounced at higher 360 
concentration, CCM@ZIF-L induced 81 % decrease in cell viability compared to a 20 % decrease 361 
in cell viability by free curcumin at the equivalent concentration of 5 μg/ml. The significant 362 
improvement of the cytotoxicity of CCM@ZIF-L on A549 cells can be attributed to the protective 363 
encapsulation of ZIF-L and the effective sustainable drug release. According to the result of 364 
stability experiment, free curcumin would sharp degrade in short time. However, CCM@ZIF-L 365 
showed the excellent stability due to the ZIF-L encapsulation. Additionally, CCM@ZIF-L 366 
achieved the effective sustainable release of curcumin for a long time in acidic cancer cells 367 
environment. In summary, the results of cytotoxicity assay indicated clearly that the CCM@ZIF-368 
L displayed obvious inhibition effects on cell proliferation.56  369 
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Figure 5. (A) In vitro biocompatibility of ZIF-L against A549 cells. (B) In vitro cytotoxicity of 371 
free curcumin and CCM@ZIF-L against A549 cells at different concentrations for 72 h.  372 
3.5 Cellular uptake of encapsulated curcumin 373 
The effective internalization of drugs into cancer cells would be a crucially important process 374 
for any cancer treatment.41 The cellular uptake of curcumin and CCM@ZIF-L on A549 cells was 375 
investigated by employing CLSM. The uni-laminar A549 cells were incubated with free curcumin 376 
and CCM@ZIF-L at the equivalent drug concentration of 5 μg/ml for 4 h. For comparison, A549 377 
cells were also treated with DMSO instead of drug as a control treatment. The commercial 378 
fluorescent dye PI was used to characterize morphology of cell, and the green fluorescence of 379 
curcumin indicated the drug distribution in cells. As shown in Figure 6, the red fluorescent 380 
intensity of CCM@ZIF-L was similar to that of free curcumin. In contrast, CCM@ZIF-L showed 381 
significantly stronger green fluorescence intensity than free curcumin, indicating that A549 cells 382 
displayed higher accumulations of curcumin than cells treated with free curcumin. According to 383 
the stability experiment, ZIF-L encapsulated curcumin was stable under physiological conditions 384 
and the pH-responsive behavior made curcumin release around cancer cell. The positive zeta 385 
potential of CCM@ZIF-L (Figure 2C) can promote the electrostatic interactions with cellular 386 
membranes (with negative potential).57 Hence, curcumin can be released in close proximity of 387 
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cancer cell membrane and readily taken up by cancer cells. In short, ZIF-L could be used as an 388 
efficient safe carrier to protect curcumin against degradation and enhance the bioavailability of 389 
curcumin by effective cellular internalization.  390 
 391 
Figure 6. CLSM images on A549 cells incubated with DMSO (A), free curcumin (B) and 392 
CCM@ZIF-L (C) at the equivalent curcumin concentration (5 μg/mL) for 4 h, respectively. Each 393 
series can be classified to the cell nucleus (red fluorescence, stained by PI), free curcumin or 394 
CCM@ZIF-L (green fluorescence); all scale bars are 20 μm. 395 
3.6 Cellular Anti-oxidant Activity 396 
Previous studies have shown that curcumin has significant antioxidant activity.58 To verify 397 
the effect of encapsulation on the antioxidant activity of curcumin, MGC-803 cells were chosen 398 
as an oxidative cell model to assess the cellular antioxidant activity (CAA) of free curcumin and 399 
encapsulated curcumin (CCM@ZIF-L). In keeping with the CAA principles45, peroxy radicals 400 
produced by ABAP could cause the oxidation of DCFH to form the fluorescent DCF. The 401 
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subsequent DCF fluorescence intensity would then be representative of the magnitude of the 402 
cellular oxidation damage caused by the presence of free radicals. Along the same vein, the 403 
antioxidant capacity of any antioxidant could be reflected by the reduced DCF fluorescence 404 
intensity. CCM@ZIF-L showed the highest free radical scavenging capacity in MGC 803 cells 405 
compared to free curcumin or ZIF-L (Figure 7A). The CAA value can be calculated according to 406 
equation (3). The CAA value of CCM@ZIF-L (69.8) was higher than free curcumin (31.4) and 407 
ZIF-L (10.9) (Figure 7B), indicating that the cellular anti-oxidant activity of curcumin was 408 
enhanced by the encapsulation of curcumin in  ZIF-L. Moreover, it was confirmed again that 409 
ZIF-L can significantly enhance cell internalization and improve bioavailability of hydrophobic 410 
drugs. 411 
 412 
Figure 7. Cellular antioxidant activity of curcumin and CCM@ZIF-L. (A) The kinetics curve of 413 
DCF fluorescence from cellular antioxidant activity (CAA) of free curcumin, ZIF-L, CCM@ZIF-414 
L, control, and blank sample. (B) Cellular antioxidant activity values of different nanoparticles.  415 
3.7 Tyrosinase inhibitory activity 416 
The catalytic activity of tyrosinase is the key to control the production of melanin, and 417 
curcumin is known to reduce the production of melanin by inhibiting the activity of tyrosinase.48 418 
 22
The tyrosinase inhibitory activity of curcumin and CCM@ZIF-L was examined in vitro. The 419 
inhibition percentage of curcumin and CCM@ZIF-L was enhanced with the increase of 420 
concentration among the evaluated range. The inhibition of tyrosinase by free curcumin at 0.5 421 
μg/ml was found to be 6.5 %, which increased to 36.5 % when the concentration of curcumin was 422 
increased ten-fold to 5 μg/ml (Figure S6).  In comparison, the antioxidant scavenging capacity of 423 
CCM@ZIF-L at 0.5 μg/ml was found to be 29.7 %. Hence, curcumin encapsulated in ZIF-L 424 
(CCM@ZIF-L) facilitated a much more effective anti-tyrosinase activity compared to free 425 
curcumin at the same concentration. This improvement may be due to the enhanced dispersibility 426 
and stability of curcumin in aqueous solution after ZIF-L encapsulation.  427 
 428 
4. Conclusion 429 
In summary, we proposed a synthesis process of encapsulating insoluble drugs with ZIF-L by 430 
the antisolvent coprecipitation method. The prepared CCM@ZIF-L possessed high DLE (98.21 431 
%) and the regular leaf or cruciate flower-like structure. The results of SEM, TEM, CLSM, FTIR, 432 
XRD and zeta-potential suggested the great encapsulation of curcumin was achieved by ZIF-L. 433 
CCM@ZIF-L showed superior stability to free curcumin under different temperatures, pH or light 434 
conditions due to the protective encapsulation of ZIF-L. In vitro drug release results revealed an 435 
81.2 % drug release a 72 h period in simulated tumor acidic conditions, implying that CCM@ZIF-436 
L performed the pH-sensitive release behavior. Cytotoxicity and cellular internalization results 437 
showed enhanced anticancer activity of CCM@ZIF-L against A549 cells. Moreover, the cellular 438 
antioxidant activity of ZIF-L loaded curcumin was significantly improved than free curcumin on 439 
MGC-803 cells. Therefore, our pH-sensitive drug delivery system based on the microcrystal of an 440 
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insoluble drug provided a promising potential in cancer treatment for broadening the applications 441 
of MOF in biomedical field. 442 
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